Combined modality therapy of esophageal cancer.

Combined modality therapy of esophageal cancer.

Item
http://www.wikidata.org/entity/Q37300119
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library.Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models.MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.Clinical T2N0M0 carcinoma of thoracic esophagusInhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage checkpoint.Accomplishments in 2008 in the management of esophageal cancerNeoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma.
P2860

Combined modality therapy of esophageal cancer.

Item
http://www.wikidata.org/entity/Q37300119
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined modality therapy of esophageal cancer.
@en
Combined modality therapy of esophageal cancer.
@nl
type
label
Combined modality therapy of esophageal cancer.
@en
Combined modality therapy of esophageal cancer.
@nl
prefLabel
Combined modality therapy of esophageal cancer.
@en
Combined modality therapy of esophageal cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Combined modality therapy of esophageal cancer.
@en
P2093
P304
P31
P356
P433
P478
P577
P698